LONDON & SEATTLE–(BUSINESS WIRE)–#ophthalmology—Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced participation in four upcoming eye care conferences. The Company’s lead investigational asset, BRIMOCHOL™ PF, is designed to be the first and only combination therapy for presbyopia and has received a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026. Tenpoint Therapeutics is actively advancing preparations for a commercial launch in 1H 2026.
Medical Conferences
- Vision Expo West 2025 (Las Vegas, NV), September 17-20. Vision Expo is recognized as the most comprehensive event for the entire vision community.
- Academy 2025 Boston presented by the American Academy of Optometry (Boston, MA), October 8-11. Academy 2025 Boston offers an opportunity to explore the latest advancements in optometry with more than 150 industry-leading exhibitors, innovative papers and posters, and networking opportunities. Visit Tenpoint Therapeutics at Booth 1833.
- Eyecelerator at AAO (Orlando, FL), October 16. Eyecelerator provides a full day of KOL-driven programs highlighting industry advancements, investment trends, and innovative new products disrupting eye care.
- The American Academy of Ophthalmology Annual Meeting 2025 (Orlando, FL), October 17-20. This conference brings leaders in the profession together with physicians from across the world for a premier educational experience. Visit Tenpoint Therapeutics at Booth 537.
About Tenpoint Therapeutics
Tenpoint Therapeutics Ltd. is a global, commercial-ready biotechnology company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its lead asset, BRIMOCHOL™ PF, is a novel pupil-modulating, investigational therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately two billion people globally. Tenpoint has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) for BRIMOCHOL™ PF, has filed the NDA and has received a Prescription Drug User Fee Act (PDUFA) date from the US FDA of Jan 28, 2026. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts, and geographic atrophy.
To learn more, visit tenpointtherapeutics.com and connect on LinkedIn.
Contacts
Media:
Nina Gill
LaVoieHealthScience
ngill@lavoiehealthscience.com
781-856-3103
Investors:
Casey Darby
LaVoieHealthScience
tenpoint@lavoiehealthscience.com
847-964-3281